Allianz Asset Management
TPTX

Allianz Asset Management’s Turning Point Therapeutics, Inc. Common Stock TPTX Stock Holding History

Allianz Asset Management’s Portfolio TPTX Stock Details TPTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-366,453
Closed -$27.6M – 2213
2022
Q2 		$27.6M Buy
366,453
+351,814
+2,403% +$15.6M 0.03% 579
2022
Q1 		$393K Sell
14,639
-46,615
-76% -$1.57M ﹤0.01% 2172
2021
Q4 		$2.93M Sell
61,254
-87,774
-59% -$3.92M ﹤0.01% 1461
2021
Q3 		$9.9M Buy
149,028
+58,814
+65% +$4.19M 0.01% 1019
2021
Q2 		$7.04M Buy
90,214
+33,373
+59% +$2.47M 0.01% 969
2021
Q1 		$5.38M Sell
56,841
-10,001
-15% -$1.19M 0.01% 1034
2020
Q4 		$8.14M Buy
66,842
+5,513
+9% +$604K 0.01% 905
2020
Q3 		$5.36M Buy
61,329
+4,649
+8% +$324K 0.01% 960
2020
Q2 		$3.66M Sell
56,680
-12,930
-19% -$746K ﹤0.01% 1340
2020
Q1 		$3.11M Buy
69,610
+24,883
+56% +$1.32M ﹤0.01% 1365
2019
Q4 		$2.79M Sell
44,727
-15,621
-26% -$743K ﹤0.01% 1738
2019
Q3 		$2.27M Buy
60,348
+47,290
+362% +$2.06M ﹤0.01% 1780
2019
Q2 		$531K Buy
+13,058
New +$466K ﹤0.01% 2327

Allianz Asset Management's TPTX Position: Q3 2022 in Review

Allianz Asset Management sold out of Turning Point Therapeutics, Inc. Common Stock (TPTX) in Q3 2022, closing a stake of 366,453 shares — an estimated $27.6M sold.

Allianz Asset Management first reported a position in TPTX in Q2 2019 and held it in 13 quarters. The position peaked at $27.6M in Q2 2022. 0 funds tracked by Wall St. Rank hold TPTX as of Q3 2022.

  • Allianz Asset Management reported no remaining Turning Point Therapeutics, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
  • Allianz Asset Management sold 366,453 Turning Point Therapeutics, Inc. Common Stock shares in Q3 2022, an estimated $27.6M.
  • Allianz Asset Management first reported a position in Turning Point Therapeutics, Inc. Common Stock in Q2 2019 and held it in 13 quarters.
  • Allianz Asset Management's Turning Point Therapeutics, Inc. Common Stock position peaked at $27.6M in Q2 2022.
  • 0 funds tracked by Wall St. Rank held Turning Point Therapeutics, Inc. Common Stock as of Q3 2022.

Based on Allianz Asset Management's 13F filing for Q3 2022, filed 8 Nov 2022.